8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Dec 15, 2025·SEC
BeyondSpring Inc.(BYSI)Earnings, Financials & Key Ratios
BYSI•NASDAQ
$1.66
Price updated Jul 7, 2026
AboutBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$9M-4.6%
- Net Income-$8M+28.1%
- EPS (Diluted)-0.20+28.6%
BYSI Price & Volume
BeyondSpring Inc. (BYSI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Viability
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's inability to generate consistent revenue
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- BeyondSpring remains a high-risk, pre-commercial entity characterized by a lack of recurring revenue and a rapidly depleting capital base.
- The company's reliance on speculative milestone payments and the failure to secure FDA approval for its lead asset, Plinabulin, create significant regulatory and liquidity headwinds.
- Investors should exercise extreme caution as the firm's negative equity position and consistent operational losses suggest a high probability of future dilutive financing or insolvency.
Verdict Logic
combined with a rapid decline in total assets from $37.1 million to $18.4 million over the last year, indicates a critical risk of insolvency.
BYSI Growth Metrics
BeyondSpring Inc. (BYSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-153.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-146.3%
Return on Capital
10 Years-192.62%
5 Years-59.32%
3 Years-49.3%
Last Year-50.17%
BYSI Recent Earnings
BeyondSpring Inc. (BYSI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (100%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.05+90.7%
$0.54
Rev
—
$9M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.05+90.3%
$0.54
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.05
—
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.04
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.05vs $0.54+90.7% | —vs $9M |
| Q2 2026 | Mar 25, 2026 | $0.05vs $0.54+90.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.05 | — |
| Q3 2025 | Aug 13, 2025 | $0.04 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BeyondSpring Inc. (BYSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.66 | $68.26M | -8.30 | — | — | — | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Compare BYSI vs Peers
BeyondSpring Inc. (BYSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BYSI SEC Filings & Documents
BeyondSpring Inc. (BYSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BYSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BYSI Frequently Asked Questions
BeyondSpring Inc. (BYSI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BYSI profitable?
BeyondSpring Inc. (BYSI) reported a net loss of $7.6M for fiscal year 2025.
Dividend & Returns
What is BeyondSpring Inc.'s free cash flow?
BeyondSpring Inc. (BYSI) had negative free cash flow of $19.1M in fiscal year 2025, likely due to heavy capital investments.